Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B L Lum

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Cancer Treatment and Research|January 1, 1994
Clinical reversal of multidrug resistanceB I Sikic, G A Fisher, B L Lum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistanceN L Bartlett, B L Lum, G A Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1983
Weekly doxorubicin in endocrine-refractory carcinoma of the prostateF M Torti, D Aston, B L Lum, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 10, 2001
Primary leiomyosarcoma of the vagina. A case report and literature reviewG. Ciaravino, D. S. Kapp, A. M. Vela, et al.
Cancer|December 1, 1993
Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerationsB L Lum, G A Fisher, N A Brophy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH studyC Jackisch, S-B Kim, V Semiglazov, et al.
Cancer|December 1, 1985
A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinomaF M Torti, L D Shortliffe, S K Carter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1992
Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistanceA M Yahanda, K M Alder, G A Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1992
Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistanceB L Lum, S Kaubisch, A M Yahanda, et al.
Leukemia|May 3, 2002
Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemiaN J Lacayo, B L Lum, D L Becton, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Cancer Treatment and Research|January 1, 1994
Clinical reversal of multidrug resistanceB I Sikic, G A Fisher, B L Lum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistanceN L Bartlett, B L Lum, G A Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1983
Weekly doxorubicin in endocrine-refractory carcinoma of the prostateF M Torti, D Aston, B L Lum, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 10, 2001
Primary leiomyosarcoma of the vagina. A case report and literature reviewG. Ciaravino, D. S. Kapp, A. M. Vela, et al.
Cancer|December 1, 1993
Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerationsB L Lum, G A Fisher, N A Brophy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH studyC Jackisch, S-B Kim, V Semiglazov, et al.
Cancer|December 1, 1985
A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinomaF M Torti, L D Shortliffe, S K Carter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1992
Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistanceA M Yahanda, K M Alder, G A Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1992
Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistanceB L Lum, S Kaubisch, A M Yahanda, et al.
Leukemia|May 3, 2002
Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemiaN J Lacayo, B L Lum, D L Becton, et al.
Pageof 6